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Background
The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that 
platelets play in abetting cancer growth are unclear.
Methods
We analyzed clinical data on 619 patients with epithelial ovarian cancer to test asso-
ciations between platelet counts and disease outcome. Human samples and mouse 
models of epithelial ovarian cancer were used to explore the underlying mechanisms 
of paraneoplastic thrombocytosis. The effects of platelets on tumor growth and an-
giogenesis were ascertained.
Results
Thrombocytosis was significantly associated with advanced disease and shortened 
survival. Plasma levels of thrombopoietin and interleukin-6 were significantly elevated 
in patients who had thrombocytosis as compared with those who did not. In mouse 
models, increased hepatic thrombopoietin synthesis in response to tumor-derived 
interleukin-6 was an underlying mechanism of paraneoplastic thrombocytosis. Tumor-
derived interleukin-6 and hepatic thrombopoietin were also linked to thrombocytosis 
in patients. Silencing thrombopoietin and interleukin-6 abrogated thrombocytosis in 
tumor-bearing mice. Anti–interleukin-6 antibody treatment significantly reduced plate-
let counts in tumor-bearing mice and in patients with epithelial ovarian cancer. In 
addition, neutralizing interleukin-6 significantly enhanced the therapeutic efficacy of 
paclitaxel in mouse models of epithelial ovarian cancer. The use of an antiplatelet 
antibody to halve platelet counts in tumor-bearing mice significantly reduced tumor 
growth and angiogenesis.
Conclusions
These findings support the existence of a paracrine circuit wherein increased produc-
tion of thrombopoietic cytokines in tumor and host tissue leads to paraneoplastic 
thrombocytosis, which fuels tumor growth. We speculate that countering paraneoplas-
tic thrombocytosis either directly or indirectly by targeting these cytokines may have 
therapeutic potential. (Funded by the National Cancer Institute and others.)
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Platelets are highly reactive cellu-lar effectors of hemostasis, immunity, and inflammation.1 The concept that platelets 
play key roles in cancer growth and metastasis is 
long-standing. In fact, the clinical observation that 
thrombocytosis (defined as a platelet count of 
>450,000 per cubic millimeter) occurs in patients 
with solid tumors was made more than 100 years 
ago.2,3 Nearly 40% of persons incidentally found 
to have platelet counts exceeding 400,000 per cu-
bic millimeter in the absence of iron deficiency 
and benign inflammatory conditions have an oc-
cult cancer, most commonly a primary gastroin-
testinal, lung, breast, or ovarian cancer.4 Beyond 
clinical observations, experimental evidence sug-
gests that platelets actively promote cancer pro-
gression through diverse mechanisms, including 
protection of cancer cells from immune surveil-
lance, negotiation of cancer-cell arrest in the micro-
vasculature, and stimulation of angiogenesis.5
Given the short life span of a circulating plate-
let, approximately 1011 platelets must be pro-
duced daily to maintain a normal platelet count in 
adults.6,7 This high baseline level of production has 
the potential to markedly increase in the context 
of cancer. The mechanisms underlying this surge 
in platelets as well as its biologic significance are 
not well understood and are the focus of the cur-
rent study. We investigated the potential clinical 
and biologic implications of a paracrine circuit that 
promotes megakaryopoiesis and thrombocytosis 
in the context of ovarian cancer.
Me thods
Clinical Data
After approval by the local institutional review 
boards, clinical data, including history of coex-
isting inflammatory conditions, were collected 
on 619 consecutive patients with primary epithe-
lial ovarian cancer from four U.S. academic 
medical centers. The effect of treatment with an 
antihuman interleukin-6 antibody (siltuximab 
[CNTO 328], at a dose of 5.4 mg per kilogram of 
ideal body weight infused once every 2 weeks) 
on platelet counts in 18 patients with ovarian can-
cer was evaluated as part of a phase 1 and 2 study 
(EudraCT number, 2006-005704-13).8 Patients 
provided written informed consent for partici-
pation in this trial and for use of their banked 
specimens in the laboratory studies pertaining 
to this investigation.
Mouse Models
All in vivo experiments in animals were approved 
by the institutional animal care and use committee. 
The development and characterization of the ortho-
topic mouse models of epithelial ovarian cancer 
have been described previously.9-13 Additional de-
tails regarding in vivo experiments with small in-
terfering RNA (siRNA) delivery (Fig. 1A and 1B in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org), siltuximab, 
antiplatelet antibody (Emfret Analytics) (Fig. 2A 
through 2E in the Supplementary Appendix), in-
flammatory agents, and platelets from transgenic 
mice that express yellow fluorescent protein (YFP) 
are described in the Supplementary Appendix.
Laboratory Measures
Plasma levels of key thrombopoietic factors were 
measured with the use of human cytokine immu-
nobead panels (Milliplex, Millipore) coupled with 
a multiplex assay (involving xMAP technology, 
Luminex) or with enzyme-linked immunosorbent 
assays (ELISA) (Quantikine, R&D Systems). Real-
time reverse-transcriptase–polymerase-chain-reac-
tion (RT-PCR) assays were performed with whole 
RNA extracted from tumor specimens (obtained 
from 46 patients) or liver specimens (from 10 pa-
tients and 10 mice) with the use of primer sets 
specific for human interleukin-6 and murine or hu-
man thrombopoietin, respectively, as previously 
described.9,14,15 Proliferation index and microves-
sel density were evaluated by staining for Ki67 
and CD31 antigens, respectively.16,17 Dual immu-
nofluorescence staining for CD31 and desmin and 
for CD31 and terminal deoxynucleotidyl transfer-
ase dUTP biotin nick end labeling (TUNEL) was 
used to assess pericyte coverage and apoptotic tu-
mor and endothelial cells, respectively.18 The in 
vitro effects of gel-filtered platelets (see the Sup-
plementary Appendix) on cell migration and pro-
liferation in epithelial ovarian cancer were evalu-
ated with the use of two-chamber chemotaxis 
and bromodeoxyuridine flow-cytometric assays 
(Click-iT EdU, Invitrogen), respectively.19
Statistical Analysis
Associations between platelet count and clinico-
pathological variables were tested in 619 patients 
with newly diagnosed epithelial ovarian cancer 
with the use of Fisher’s exact test. Kaplan–Meier 
survival curves were generated and compared with 
the use of a log-rank statistic. Multivariate analysis 
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of these data was performed with the Cox pro-
portional-hazards model. To determine whether 
plasma thrombopoietic cytokine levels were as-
sociated with platelet counts in 150 patients with 
newly diagnosed epithelial ovarian cancer, we cal-
culated Spearman’s rank-correlation coefficient for 
each pairwise association and tested for a signifi-
cant difference from 0. We used Wilcoxon rank-
sum tests to determine differences in thrombo-
poietic cytokines between patients with normal 
platelet counts (150,000 to 450,000 per cubic mil-
limeter) and those with high counts (>450,000 per 
cubic millimeter).
For interleukin-6 analysis, we used a level close 
to the median to classify patients with newly di-
agnosed epithelial ovarian cancer as having low 
interleukin-6 levels (≤10 pg per milliliter, 143 pa-
tients) or high levels (>10 pg per milliliter, 167 pa-
tients). Pearson’s correlation was used to calculate 
correlations between continuous variables. For 
preclinical data, Student’s t-test was used to test 
differences in sample means, with a sample of 
10 mice per group (80% power to detect a 50% 
reduction in tumor weight at a 5% level of statis-
tical significance). All testing was two-sided, and 
a P value of less than 0.05 was considered to in-
dicate statistical significance. All analyses were 
completed with SAS software, version 9.1 for PC 
(SAS Institute).
R esult s
Clinical Implications of Paraneoplastic 
Thrombocytosis
The mean (±SD) platelet count in patients with 
epithelial ovarian cancer and thrombocytosis was 
558,410±90,010 per cubic millimeter (median, 
542,000 per cubic millimeter) and without throm-
bocytosis was 316,570±70,140 per cubic millimeter 
(median, 318,000 per cubic millimeter) (Table 1 in 
the Supplementary Appendix). Thirty-one percent 
of the patients (192 of 619) had thrombocytosis 
at the time of initial diagnosis of epithelial ovarian 
cancer. Less than 2% of the patients had a coex-
isting nonmalignant inflammatory condition, and 
none of these patients had thrombocytosis at ini-
tial presentation. Although women with thrombo-
cytosis had slightly lower hemoglobin levels than 
those with normal platelet counts (mean hemo-
globin level, 11.9 vs. 12.7 g per deciliter; P<0.001), 
mean corpuscular volume and serum ferritin lev-
els did not differ significantly between the two 
groups (Table 2 in the Supplementary Appendix). 
These data suggest that other inflammatory con-
ditions and iron deficiency are unlikely to be re-
sponsible for the thrombocytosis observed in wom-
en with epithelial ovarian cancer.
Patients with thrombocytosis were significant-
ly more likely to have advanced-stage disease, 
vascular thromboembolic complications, and high-
er preoperative levels of cancer antigen 125 than 
those with normal platelet counts (Fig. 3 in the 
Supplementary Appendix). Women with platelet 
counts of more than 450,000 per cubic millimeter 
had a significantly shorter median time to disease 
progression than those with normal platelet counts 
(Fig. 1A). The median overall survival among 
patients with thrombocytosis was 2.62 years, as 
compared with 4.65 years among those with 
normal platelet counts (P<0.001) (Fig. 1B). In the 
multivariate model that included age, disease 
stage, tumor grade, histologic type, and extent 
of surgical cytoreduction, thrombocytosis re-
mained an independent predictor of compro-
mised survival (P<0.001) (Table 3 in the Supple-
mentary Appendix).
Paraneoplastic Thrombocytosis in Mouse 
Models of Epithelial Ovarian Cancer
On the basis of the clinical findings described 
above, we evaluated the effect of cancer on platelet 
counts in orthotopic mouse models of epithelial 
ovarian cancer. As compared with platelet counts 
in control mice, those in mice with epithelial ovar-
ian cancer were increased by 30 to 130% (P = 0.009 
for HeyA8, P = 0.003 for A2780ip2, and P = 0.001 
for 2774 mouse models) (Fig. 4A in the Supple-
mentary Appendix). Platelet counts correlated sig-
nificantly with tumor burden (r = 0.78, P<0.001) 
and number of intraperitoneal metastases (r = 0.65, 
P = 0.004) (Fig. 4B and 4C in the Supplementary 
Appendix). Platelet counts were also increased by 
59 to 64% in two syngeneic mouse models of 
ovarian cancer (P = 0.01) (Fig. 4D in the Supple-
mentary Appendix). To assess generalizability, we 
also quantified platelets in mouse models of breast 
cancer (GILM2 cells), uterine cancer (Ishikawa 
cells), and pancreatic cancer (heterotopic human 
pancreatic xenografts). Platelet counts were sig-
nificantly increased in the models of uterine and 
pancreatic cancer but not in the breast-cancer 
model (Fig. 4E in the Supplementary Appendix).
To better understand the temporal relationship 
between tumor growth and thrombocytosis, we 
carried out a longitudinal assessment of platelet 
counts in HeyA8–luciferase-positive tumor-bearing 
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mice. Platelet counts began to rise when a tumor 
was detected by bioluminescence imaging and 
increased in parallel with grossly measurable dis-
ease (Fig. 5 in the Supplementary Appendix).
An Underlying Mechanism of Paraneoplastic 
Thrombocytosis
To test the hypothesis that factors produced by can-
cer cells or host tissues (or both) stimulate mega-
karyopoiesis and paraneoplastic thrombocytosis, 
we first enumerated megakaryocytes in the bone 
marrow and spleens from tumor-bearing mice. 
Mean platelet counts strongly correlated with mean 
medullary and splenic megakaryocyte counts 
(r = 0.95, P = 0.01). As compared with medullary 
and splenic megakaryocyte counts in controls, 
those in tumor-bearing mice were increased by a 
factor of 2 to 3 and 7 to 13, respectively (P<0.001) 
(Fig. 6A in the Supplementary Appendix). To de-
termine whether the findings would be similar in 
patients with epithelial ovarian cancer, we surveyed 
our clinical data set for women who underwent a 
bone marrow biopsy. Among the eight patients in 
whom a bone marrow biopsy was performed, plate-
let counts correlated with megakaryocyte density 
(two patients with thrombocytosis had megakaryo-
cyte hyperplasia, four patients had normal platelet 
and megakaryocyte counts, and two patients had 
thrombocytopenia and megakaryocyte hypoplasia) 
(Fig. 6B in the Supplementary Appendix).
Next, we considered the possible involvement of 
humoral factors known to physiologically regulate 
megakaryopoiesis and platelet production. We 
quantified plasma levels of 10 key thrombopoietic 
factors in an independent cohort of 150 patients 
with newly diagnosed epithelial ovarian cancer 
(31% of whom had thrombocytosis, a frequency 
consistent with that in the initial cohort). Plate-
let counts correlated significantly with plasma 
interleukin-6 levels (Spearman’s rank-correlation 
coefficient, 0.37; P<0.001) and thrombopoietin 
levels (Spearman’s rank-correlation coefficient, 
0.29; P<0.001) (Table 4 in the Supplementary Ap-
pendix). Plasma levels of interleukin-6 and throm-
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Figure 1. Clinical Significance of and Thrombopoietic 
Cytokines Associated with Paraneoplastic Thrombocytosis 
in Patients with Epithelial Ovarian Cancer.
Panel A shows Kaplan–Meier survival curves for  
progression-free survival according to platelet count at 
initial diagnosis among patients with epithelial ovarian 
cancer, and Panel B shows curves for overall survival. 
Panel C shows mean plasma levels of interleukin-6 in 
104 patients with epithelial ovarian cancer and normal 
platelet counts and 46 patients with epithelial ovarian 
cancer and thrombocytosis, and Panel D shows mean 
plasma levels of thrombopoietin in the same patients. 
T bars indicate standard deviations. Thrombocytosis 
was defined as a platelet count of more than 450,000 
per cubic millimeter.
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bopoietin were significantly elevated in patients 
with thrombocytosis (Fig. 1C and 1D, and Table 
5 in the Supplementary Appendix).
Plasma levels of human interleukin-6, but not 
mouse interleukin-6, were significantly elevated in 
all mouse models of epithelial ovarian cancer that 
were tested (Fig. 7A in the Supplementary Appen-
dix). Thrombopoietin is mainly synthesized by the 
liver at a fixed rate, but little is known about the 
influence of disease states such as cancer on he-
patic thrombopoietin production.20 In liver spec-
imens resected from both control and tumor-
bearing mice, levels of hepatic thrombopoietin 
messenger RNA were 38 to 64% higher in tumor-
bearing mice (P = 0.43 for the 2774 mouse model 
and P<0.001 for the A2780ip2 and HeyA8 mouse 
models of epithelial ovarian cancer) (Fig. 7B in 
the Supplementary Appendix).
On the basis of data suggesting that interleu-
kin-6 enhances hepatic thrombopoietin synthe-
sis,21,22 we measured platelet counts and plasma 
thrombopoietin levels in tumor-bearing (ID8VEGF-164
syngeneic model) mice that lacked functional he-
patocyte interleukin-6 receptors. Thrombocytosis 
was not observed in these mice (Fig. 2A). Further-
more, the mean plasma thrombopoietin level was 
33% lower in the tumor-bearing mice that lacked 
functional hepatocyte interleukin-6 receptors than 
in tumor-bearing mice with functional receptors 
(flox/flox controls) (Fig. 7C in the Supplementary 
Appendix). These findings suggest that increased 
hepatic thrombopoietin synthesis in response to 
tumor-derived interleukin-6 is an underlying mech-
anism of paraneoplastic thrombocytosis (Fig. 2B).
To determine whether this paracrine signaling 
is the basis for paraneoplastic thrombocytosis in 
humans, we quantified tumor and plasma inter-
leukin-6 levels in a subset of 46 patients with 
newly diagnosed epithelial ovarian cancer, using 
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Figure 2. Underlying Mechanism of Paraneoplastic 
Thrombocytosis in Epithelial Ovarian Cancer.
Panel A shows mean platelet counts in non–tumor-
bearing (NTB) mice, tumor-bearing (TB) mice, and TB 
mice that lacked functional hepatocyte interleukin-6 re-
ceptors (TB IL-6R–null mice). T bars indicate standard 
errors; for NTB mice, the standard error is too small to 
be shown. Panel B shows the proposed paracrine sig-
naling pathway that mediates paraneoplastic thrombo-
cytosis in epithelial ovarian cancer. Interleukin-6 secreted 
by ovarian cancer cells stimulates hepatic thrombopoietin 
(TPO) production. This drives thrombopoiesis in the 
bone marrow, giving rise to thrombocytosis. Panel C 
shows Kaplan–Meier survival curves for overall surviv-
al according to plasma interleukin-6 levels. Median 
overall survival among patients with plasma interleu-
kin-6 levels of more than 10 pg per milliliter was 3.38 
years, as compared with 5.99 years among those with 
levels of 10 pg per milliliter or less.
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a quantitative RT-PCR assay and ELISA, respec-
tively. A strong correlation between tumor and 
plasma interleukin-6 levels was observed (r = 0.8, 
P<0.001) (Fig. 8A in the Supplementary Appendix). 
Moreover, mean tumor interleukin-6 levels were 
significantly higher in patients with thrombocy-
tosis than in those with normal platelet counts 
(Fig. 8B in the Supplementary Appendix). Interleu-
kin-6 levels were also significantly associated with 
plasma thrombopoietin levels (Spearman’s rank-
correlation coefficient, 0.6; P<0.001). We also used 
a quantitative RT-PCR assay to examine 10 liver 
samples removed from patients with epithelial 
ovarian cancer during cytoreductive surgery. He-
patic thrombopoietin expression closely paralleled 
platelet counts (r = 0.64, P = 0.04) (Fig. 8C in the 
Supplementary Appendix).
To better understand the clinical significance of 
this paracrine-mediated paraneoplastic thrombo-
cytosis, we evaluated the effect of circulating inter-
leukin-6 levels on progression-free and overall 
survival among 310 patients with epithelial ovari-
an cancer. In univariate analyses, patients with 
plasma interleukin-6 levels that were 10 pg per 
milliliter or lower had improved progression-free 
survival (Fig. 8D in the Supplementary Appendix) 
and overall survival (Fig. 2C), as compared with 
patients who had plasma interleukin-6 levels that 
were higher than 10 pg per milliliter. In multi-
variate models, plasma interleukin-6 levels of 
more than 10 pg per milliliter and platelet counts 
of more than 450,000 per cubic millimeter re-
mained independent predictors of a poor progno-
sis even after adjustment for stage, grade, and 
volume of residual disease after cytoreductive 
surgery.
Next, to ascertain whether interleukin-6 and 
thrombopoietin play functional roles in parane-
oplastic thrombocytosis, we tested the effect of 
silencing these factors on thrombocytosis in the 
A2780ip2 orthotopic mouse model. The combina-
tion of interleukin-6 and thrombopoietin siRNA 
was most effective, completely abrogating throm-
bocytosis (Fig. 3A). We also explored the thera-
peutic value of targeting interleukin-6 with siltux-
imab (humanized anti–interleukin-6 antibody), 
paclitaxel (a chemotherapeutic agent commonly 
used in epithelial ovarian cancer), or the two 
agents combined. Siltuximab or paclitaxel mono-
therapy significantly reduced tumor growth in 
mouse models of epithelial ovarian cancer (2774 
and A2780ip2 models). Combination treatment 
was most effective, reducing tumor growth by 
more than 90% in both models. Assessment of 
platelet counts at the conclusion of treatment 
revealed that siltuximab blocked the thrombocyto-
sis characteristic of untreated tumor-bearing mice 
(Fig. 9A and 9B in the Supplementary Appendix). 
Moreover, platelet counts rebounded by 34% with-
in 10 days after the end of siltuximab therapy, 
pointing to the direct role of tumor-derived inter-
leukin-6 in thrombocytosis.
To support these in vivo data with human 
clinical data, we tracked platelet counts in a cohort 
of patients with ovarian cancer who received treat-
ment with single-agent siltuximab every 2 weeks 
for 12 weeks. Anti–interleukin-6 treatment resulted 
in a significant and sustained reduction in platelet 
counts, from a mean count of 356×109±147×109 
B Effect of Siltuximab Treatment on Platelet Count
A Effect of Silencing Interleukin-6 and Thrombopoietin
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Figure 3. Functional Role of Interleukin-6 and Thrombo-
poietin in Paraneoplastic Thrombocytosis.
Panel A shows the effect of silencing interleukin-6 alone, 
thrombopoietin alone, and the two in combination on 
paraneoplastic thrombocytosis in mice with epithelial 
ovarian cancer. The P value is for the difference in platelet 
counts between combination and control siRNA treat-
ment. Panel B shows the effect of siltuximab treatment 
(every 2 weeks) on platelet counts in patients with epi-
thelial ovarian cancer. I bars indicate standard devia-
tions. The term siRNA denotes small interfering RNA.
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per liter before treatment to 243×109±85×109 per 
liter after 3 weeks of treatment (P = 0.009) (Fig. 3B).
Biologic Significance of Paraneoplastic 
Thrombocytosis
To evaluate the biologic role of platelets in tumor 
growth, we used an antiplatelet antibody direct-
ed against mouse glycoprotein 1b α (at a dose of 
0.5 μg per gram of body weight) to induce a sus-
tained 50% reduction in platelets in the A2780ip2 
mouse model. Halving the circulating platelet count 
inhibited tumor growth by 50% (P = 0.03) (Fig. 4A). 
Microscopical examination of tumors from mice 
treated with antiplatelet antibody revealed substan-
tial coagulative necrosis (Fig. 4B). As compared 
with the use of control IgG, the use of antiplatelet 
antibody to deplete platelets resulted in a 44% de-
crease in proliferation (P<0.001) (Fig. 4B) and a 
51% reduction in microvessel density (P<0.001) 
(Fig. 10A in the Supplementary Appendix). Plate-
let depletion reduced pericyte coverage by 60% 
(P<0.001); tumor microvessels were predomi-
nantly devoid of pericytes, and existing pericytes 
appeared to be loosely attached (Fig. 10B in the 
Supplementary Appendix).18,23 Platelet depletion 
with the use of antiplatelet antibody, as compared 
with control IgG, resulted in an increase in tumor-
cell and endothelial-cell apoptosis by a factor of 
four and a factor of eight, respectively (P = 0.008 
and P<0.001, respectively) (Fig. 10C in the Supple-
mentary Appendix).
We next explored whether platelets extravasate 
into the tumor bed, ascites, or both, sites where 
direct interactions with cancer cells are more op-
portune. Platelets from transgenic mice that ex-
press YFP under the control of the promoter of 
platelet factor 4 were transfused into tumor-
bearing recipient mice (Fig. 5A). YFP-labeled plate-
lets were detected in the tumor bed, primarily in a 
perivascular location, and were found to be free-
floating and adherent to tumor cells in ascites 
(Fig. 5B).
To determine the extent to which these observa-
tions may be tumor-specific, we compared the 
number of native, extravascular platelets in tumor 
samples, in the peritoneum after the induction of 
chemical peritonitis, and in subcutaneous tissues 
after the induction of a foreign-body reaction. Ex-
travasated platelets were not observed in the con-
text of a foreign-body inflammatory reaction and 
were rarely observed in the peritoneum after a pro-
inflammatory stimulus. However, abundant plate-
lets were detected in the tumor microenvironment 
apart from the vasculature (Fig. 5C). On the basis 
of finding platelets in contact with tumor cells 
outside the bloodstream, we assessed the func-
tional effects of plasma-purified platelets on the 
proliferation and migration of epithelial ovarian 
cancer cells. Platelets significantly stimulated cell 
proliferation (Fig. 11A in the Supplementary Ap-
pendix) and migration (P<0.001 for the three cell 
lines) (Fig. 11B in the Supplementary Appendix).
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Figure 4. Antitumor Effects of Blocking Paraneoplastic Thrombocytosis.
Panel A shows the mean tumor weight in mice after treatment with either antiplatelet antibody (APA) or control IgG. 
Representative macroscopic appearances of tumors at necropsy are shown below the histogram. Panel B shows the 
effect of APA versus control IgG on tumor-cell viability (upper photomicrographs) and proliferation (lower photomicro-
graphs). The corresponding histograms show the mean necrotic tumor area and the number of cells that were posi-
tive for Ki67, normalized to the total cell count per high-power field (HPF). T bars indicate standard errors.
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Discussion
Our study shows that increased thrombopoietic 
cytokine production by tumor and host tissues is 
a major driving force for paraneoplastic throm-
bocytosis. In particular, this process is mediated 
by hepatic thrombopoietin synthesis that is in-
creased in response to excessive tumor-derived 
interleukin-6, thereby increasing platelet counts, 
which in turn promote tumor growth, creating a 
feed-forward loop.
Although paraneoplastic thrombocytosis is a 
well-recognized phenomenon in patients with can-
cer, the mechanisms underlying this observation 
are not fully defined. Findings from this study, 
derived from converging clinical information as 
well as pharmacologic and genetic manipulations, 
not only reveal the complex paracrine signaling 
responsible for paraneoplastic thrombocytosis in 
ovarian cancer but also point to the pivotal role of 
platelets in driving the biologic mechanisms of 
malignant tumors. For example, the secretory ac-
tivities of platelets may stabilize the tumor vascu-
lature and prevent intratumoral hemorrhage. The 
platelet-derived factors involved in maintaining 
angiogenic microvessel integrity and the cell type 
that platelets influence most are not fully known.24
Given the role of pericytes in supporting and sta-
bilizing small blood vessels, it is possible that 
platelets regulate tumor-vasculature homeostasis, 
in part by nurturing pericytes. Prospective collec-
tion and in-depth analysis of platelets from pa-
tients with cancer will be required to fully under-
stand the cancer-promoting role of platelets.
This aberrant paracrine signaling may have 
important clinical ramifications, since paraneo-
plastic thrombocytosis arises in a substantial pro-
portion of patients with cancer. For example, one 
in three women who have received a diagnosis of 
ovarian cancer have thrombocytosis and are thus 
at substantially increased risk for advanced dis-
ease, vascular thromboembolic complications, and 
Figure 5. Platelets in the Tumor Microenvironment.
Panel A shows the method used for detecting extrava-
sated platelets. Platelets isolated from female transgenic 
C57BL/6 mice that express yellow fluorescent protein 
(YFP) under the control of the promoter of platelet factor 
4 (PF4) were transfused by tail-vein injections into tu-
mor-bearing mice. After 1 hour, ascites was removed by 
paracentesis, and intravital fixation was performed be-
fore the resection of tumor specimens. Panel B shows 
extravascular YFP platelets in solid tumor (left: CD31, 
red; nuclei, blue) and in ascites (right: tumor cells, 
red). Panel C shows representative photomicrographs 
of tumor, normal peritoneum, and peritoneum after 
the induction of peritonitis, with immunofluorescence 
staining for CD31 and CD42b antigens to label the vas-
culature (red) and endogenous platelets (green), re-
spectively. The arrowheads indicate colocalization of 
CD31 and CD42b, indicative of intravascular platelets. 
The bar graph depicts the number of extravascular 
platelets per five random high-power fields (HPF) for 
each condition. T bars indicate standard errors.
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compromised disease-specific survival. Given that 
paraneoplastic thrombocytosis portends adverse 
clinical outcomes, countering it and using direct 
antiplatelet strategies have the potential to serve as 
a valuable therapeutic approach in humans.
Although the present investigation does not 
test this strategy in patients with cancer, such a 
premise is directly supported by epidemiologic 
studies of drugs known to interfere with cross-
talk between platelets and tumor cells. Several 
prospective clinical trials have shown that low-
molecular-weight heparin improves survival 
among patients with cancer, independently of 
the prevention of vascular thromboembolic com-
plications due to anticoagulation.25 In addition, 
a recent large prospective cohort study revealed 
that daily use of aspirin after the diagnosis of 
colorectal cancer decreases cancer-specific and 
overall mortality.26,27 These data warrant further 
consideration, particularly given that paraneo-
plastic thrombocytosis may be not simply an epi-
phenomenon of cancer progression but a contribu-
tor to the process.
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